SG Americas Securities LLC Invests $110,000 in Silence Therapeutics plc (NASDAQ:SLN) (2024)

SG Americas Securities LLC purchased a new stake in shares of Silence Therapeutics plc (NASDAQ:SLN – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,333 shares of the company’s stock, valued at approximately $110,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Goldman Sachs Group Inc. raised its holdings in shares of Silence Therapeutics by 27.1% during the first quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company’s stock worth $18,350,000 after purchasing an additional 205,815 shares during the period. Citadel Advisors LLC acquired a new stake in Silence Therapeutics during the second quarter worth about $136,000. UBS Group AG lifted its holdings in Silence Therapeutics by 4.8% in the fourth quarter. UBS Group AG now owns 69,006 shares of the company’s stock worth $1,052,000 after acquiring an additional 3,191 shares during the last quarter. Morgan Stanley boosted its stake in Silence Therapeutics by 36.0% in the fourth quarter. Morgan Stanley now owns 210,973 shares of the company’s stock valued at $3,217,000 after acquiring an additional 55,814 shares during the period. Finally, Millennium Management LLC grew its holdings in shares of Silence Therapeutics by 19.8% during the fourth quarter. Millennium Management LLC now owns 17,436 shares of the company’s stock valued at $266,000 after purchasing an additional 2,879 shares during the last quarter. 98.73% of the stock is owned by institutional investors and hedge funds.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN opened at $22.64 on Friday. The stock has a market cap of $677.62 million, a P/E ratio of -15.51 and a beta of 1.41. The firm’s 50-day simple moving average is $23.03 and its 200 day simple moving average is $17.05. Silence Therapeutics plc has a fifty-two week low of $4.55 and a fifty-two week high of $27.72. The company has a quick ratio of 4.56, a current ratio of 4.56 and a debt-to-equity ratio of 0.01.

Silence Therapeutics (NASDAQ:SLN – Get Free Report) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.22). Silence Therapeutics had a negative return on equity of 262.17% and a negative net margin of 171.41%. The company had revenue of $2.61 million during the quarter, compared to analyst estimates of $11.46 million. Equities analysts expect that Silence Therapeutics plc will post -1.38 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. BMO Capital Markets initiated coverage on Silence Therapeutics in a report on Wednesday, January 31st. They issued an “outperform” rating and a $67.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 15th. Chardan Capital upped their price target on shares of Silence Therapeutics from $26.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th. Finally, Morgan Stanley lifted their price objective on shares of Silence Therapeutics from $29.00 to $45.00 and gave the company an “overweight” rating in a research report on Thursday, March 14th.

Get Our Latest Analysis on SLN

Silence Therapeutics Profile

(Free Report)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.

Read More

• Five stocks we like better than Silence Therapeutics
• What are earnings reports?
• Comprehensive Analysis of PayPal Stock
• Stock Dividend Cuts Happen Are You Ready?
• Intuitive Surgical Stock Can Trend Much Higher This Year
• Basic Materials Stocks Investing
• Alibaba Stock Analysis: Insights, Trends, and Future Predictions

Want to see what other hedge funds are holding SLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silence Therapeutics plc (NASDAQ:SLN – Free Report).

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.